Experimental cancer pill shows early promise but study halted
Disease control
Terminated
This early-phase study tested an experimental oral drug called IK-595 in 75 adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have specific RAS or RAF gene mutations. The goal was to check safety, find the right dose, and see if it shrinks tumor…
Phase: PHASE1 • Sponsor: Ikena Oncology • Aim: Disease control
Last updated May 17, 2026 06:14 UTC